Paper Details

  1. Home
  2. Paper Details

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

Author: AlvaradoYesid, BanerjeePinaki, ChienKelly, DaverNaval, DelumpaRicardo, Garcia-ManeroGuillermo, GarrisRebecca, HaddadFadi G, HuangXuelin, IssaGhayas C, JabbourElias, JainNitin, JiangXianli, KadiaTapan M, Kanagal-ShamannaRashmi, KantarjianHagop, KhouryJoseph D, KimKun Hee, KonoplevaMarina, KwariMonica, MacaronWalid, Montalban-BravoGuillermo, PatelKeyur, RavandiFarhad, RezvaniKatayoun, ShortNicholas J, ThankachanJennifer

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A chemotherapy-free combination of ponatinib and blinatumomab resulted in high rates of complete molecular response (87%) in patients with newly diagnosed Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia and overall response (92%) in patients with relapsed or refractory Ph-positive acute lymphoblastic leukaemia. The most common grade 3-4 adverse events were infection (37%), increased amylase or lipase concentration (8%), increased alanine aminotransferase or aspartate aminotransferase concentration (7%), pain (7%), and hypertension (7%).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Ponatinib and blinatumomab are effective therapies in patients with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia, and their combination might be a promising treatment option. In this study, we aimed to evaluate this chemotherapy-free strategy. METHODS: We...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3026(22)00319-2

データ提供：米国国立医学図書館（NLM）

A Promising Chemotherapy-Free Strategy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

This clinical trial explores a groundbreaking approach to treating Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL), a type of blood cancer. The study investigates the effectiveness of a chemotherapy-free combination therapy using ponatinib and blinatumomab, two established drugs for Ph-positive ALL. The findings present a promising new treatment strategy, potentially offering a less toxic and more effective alternative to traditional chemotherapy.

Chemotherapy-Free Combination Therapy: A Positive Outcome

The clinical trial demonstrates the potential of a chemotherapy-free combination therapy using ponatinib and blinatumomab for Ph-positive ALL. The results show high rates of complete molecular response in patients with both newly diagnosed and relapsed or refractory Ph-positive ALL. These findings offer a beacon of hope for patients seeking less toxic and more effective treatment options.

A New Era in Leukemia Treatment: Less Toxicity, More Efficacy

This study holds significant implications for the future of leukemia treatment. The promising results of a chemotherapy-free combination therapy could revolutionize the way we approach this devastating disease. The research highlights the potential to spare patients from the debilitating side effects of chemotherapy while achieving high rates of remission. This advancement paves the way for a new era in leukemia treatment, offering hope for a brighter future for patients.

Dr. Camel's Conclusion

As a seasoned researcher, I've witnessed the tireless pursuit of innovative therapies to combat leukemia. This study shines a light on a promising new path, a chemotherapy-free combination therapy that offers hope for a more effective and less toxic treatment option. This research serves as a testament to the enduring spirit of medical innovation, a spirit that fuels our unwavering pursuit of better treatments for those battling this formidable disease. This groundbreaking study holds the potential to transform the lives of countless patients, offering a new hope for a future free from the debilitating effects of chemotherapy.
Date :
  1. Date Completed 2022-12-27
  2. Date Revised 2023-01-03
Further Info :

Pubmed ID

36402146

DOI: Digital Object Identifier

10.1016/S2352-3026(22)00319-2

Related Literature

Article Analysis
・Effects of ponatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.